227 related articles for article (PubMed ID: 34137164)
1. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force.
Whittle SB; Offer K; Roberts RD; LeBlanc A; London C; Majzner RG; Huang AY; Houghton P; Alejandro Sweet Cordero E; Grohar PJ; Isakoff M; Bishop MW; Stewart E; Slotkin EK; Greengard E; Borinstein SC; Navid F; Gorlick R; Janeway KA; Reed DR; Hingorani P
Pediatr Blood Cancer; 2021 Sep; 68(9):e29188. PubMed ID: 34137164
[TBL] [Abstract][Full Text] [Related]
2. Children's Oncology Group's 2023 blueprint for research: Bone tumors.
Reed DR; Grohar P; Rubin E; Binitie O; Krailo M; Davis J; DuBois SG; Janeway KA
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30583. PubMed ID: 37501549
[TBL] [Abstract][Full Text] [Related]
3. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force.
Bailey K; Cost C; Davis I; Glade-Bender J; Grohar P; Houghton P; Isakoff M; Stewart E; Laack N; Yustein J; Reed D; Janeway K; Gorlick R; Lessnick S; DuBois S; Hingorani P
F1000Res; 2019; 8():. PubMed ID: 31031965
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.
Lagmay JP; Krailo MD; Dang H; Kim A; Hawkins DS; Beaty O; Widemann BC; Zwerdling T; Bomgaars L; Langevin AM; Grier HE; Weigel B; Blaney SM; Gorlick R; Janeway KA
J Clin Oncol; 2016 Sep; 34(25):3031-8. PubMed ID: 27400942
[TBL] [Abstract][Full Text] [Related]
5. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
[TBL] [Abstract][Full Text] [Related]
6. Children's Oncology Group's 2013 blueprint for research: bone tumors.
Gorlick R; Janeway K; Lessnick S; Randall RL; Marina N;
Pediatr Blood Cancer; 2013 Jun; 60(6):1009-15. PubMed ID: 23255238
[TBL] [Abstract][Full Text] [Related]
7. Role of TKI for Metastatic Osteogenic Sarcoma.
Duffaud F
Curr Treat Options Oncol; 2020 Jun; 21(8):65. PubMed ID: 32601895
[TBL] [Abstract][Full Text] [Related]
8. OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.
Gaspar N; Campbell-Hewson Q; Huang J; Okpara CE; Bautista F
Future Oncol; 2021 Nov; 17(32):4249-4261. PubMed ID: 34382412
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
10. Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.
Harris MA; Hawkins CJ
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409176
[TBL] [Abstract][Full Text] [Related]
11. Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force.
Pacenta HL; Allen-Rhoades W; Langenau D; Houghton PJ; Keller C; Heske CM; Deel MD; Linardic CM; Shern JF; Stewart E; Turpin B; Harrison DJ; Khan J; Mascarenhas L; Skapek SX; Meyer WH; Hawkins DS; Chen EY; Amatruda JF; Hingorani P; Laetsch TW
J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33915882
[TBL] [Abstract][Full Text] [Related]
12. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group.
Isakoff MS; Goldsby R; Villaluna D; Krailo MD; Gorlick R; Doski JJ; Womer RB; Janeway KA
Pediatr Blood Cancer; 2016 Feb; 63(2):370-1. PubMed ID: 26376351
[No Abstract] [Full Text] [Related]
13. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
[TBL] [Abstract][Full Text] [Related]
14. Targeting the VEGF Pathway in Osteosarcoma.
Assi T; Watson S; Samra B; Rassy E; Le Cesne A; Italiano A; Mir O
Cells; 2021 May; 10(5):. PubMed ID: 34069999
[TBL] [Abstract][Full Text] [Related]
15. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.
Janeway KA; Barkauskas DA; Krailo MD; Meyers PA; Schwartz CL; Ebb DH; Seibel NL; Grier HE; Gorlick R; Marina N
Cancer; 2012 Sep; 118(18):4597-605. PubMed ID: 22252521
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
[TBL] [Abstract][Full Text] [Related]
17. Toward a drug development path that targets metastatic progression in osteosarcoma.
Khanna C; Fan TM; Gorlick R; Helman LJ; Kleinerman ES; Adamson PC; Houghton PJ; Tap WD; Welch DR; Steeg PS; Merlino G; Sorensen PH; Meltzer P; Kirsch DG; Janeway KA; Weigel B; Randall L; Withrow SJ; Paoloni M; Kaplan R; Teicher BA; Seibel NL; Smith M; Uren A; Patel SR; Trent J; Savage SA; Mirabello L; Reinke D; Barkaukas DA; Krailo M; Bernstein M
Clin Cancer Res; 2014 Aug; 20(16):4200-9. PubMed ID: 24803583
[TBL] [Abstract][Full Text] [Related]
18. International collaboration is feasible in trials for rare conditions: the EURAMOS experience.
Marina N; Bielack S; Whelan J; Smeland S; Krailo M; Sydes MR; Butterfass-Bahloul T; Calaminus G; Bernstein M
Cancer Treat Res; 2009; 152():339-53. PubMed ID: 20213400
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.
Isakoff MS; Goldsby R; Villaluna D; Krailo MD; Hingorani P; Collier A; Morris CD; Kolb EA; Doski JJ; Womer RB; Gorlick R; Janeway KA
Pediatr Blood Cancer; 2019 Feb; 66(2):e27524. PubMed ID: 30378256
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
